TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
active
Official procurement procedure

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Health services
UK
Published value
£26,136,000
Submission deadline 8 Jul 2026, 12:00 BST
Lots published3
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service". Published status: active. Published value: £26,136,000. 3 published lots. Recorded submission deadline: 8 Jul 2026, 12:00 BST. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
8 Jul 2026, 12:00 BST
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£26,136,000
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
24.6Bids / Report
17.4% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 391 active published awards; 367 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statusactive
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published4 Jun 2026, 16:37 BST
Last source update4 Jun 2026, 16:37 BST
Recurring procurementYes
ClassificationHealth services
Delivery area
UK
OCIDocds-h6vhtk-06ae08
What is being bought
Onasemnogene abeparvovec intravenous (Zolgensma®) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.
What changed
From the official release history
  1. Published value updated to £26,136,000
    4 Jun 2026, 16:37 BST
  2. Status changed to active
    4 Jun 2026, 16:37 BST
  3. Official notice release published
    4 Jun 2026, 16:37 BST
  4. Submission deadline changed to 8 Jul 2026, 12:00 BST
    4 Jun 2026, 16:37 BST
  5. Buyer information updated
    4 Jun 2026, 16:37 BST
Lots and requirements (3)
Published by the contracting authority
  • Lot 1 · #0
    Lot 1
    active
    Published value£8,527,000
    Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #1 and 2
    Lots 3
    active
    Published value£9,326,000
    Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 3 · #3
    Lot 2
    active
    Published value£8,283,000
    Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    4 Jun 2026, 16:37 BST
  2. Submission deadline
    8 Jul 2026, 12:00 BST
Commercial outcome and competition
AwardsNo award published
ContractsNo contract published
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-FTS-130973
View buyer profile
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published